BBLG Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 7.90%

Insider Buying (Last 12 Months): $21,661.00

Insider Selling (Last 12 Months): $0.00

Bone Biologics Insider Trading History Chart

Bone Biologics Share Price & Price History

^$0.71

▼ -0.02 (-2.74%)

As of 09/29/2023 01:00 AM ET

Days: 30 | 90 | 365

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

From Legacy Research | Ad

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret.

Most people don’t know about this facility, but it could be the most important AI project in the world.

What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details

Bone Biologics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2023	Deina H Walsh	CFO	Buy	8,000	$0.64	$5,120.00	15,000
9/11/2023	Jeff Frelick	CEO	Buy	9,500	$0.69	$6,555.00	17,204
9/6/2023	Deina H Walsh	CFO	Buy	7,000	$0.71	$4,970.00	7,000
8/31/2023	Jeff Frelick	CEO	Buy	7,600	$0.66	$5,016.00	7,704

I’ve Scored These 5 for You… (You Gotta See This)

From ProTrading Research | Ad

Statista currently value’s the AI sector at $100 billion, and expects that number to explode by twenty fold by 2030, placing its potential value at $2 trillion in under seven years.

And I’ve scored 5 stocks that could be the next big thing in Ai.

We compiled them into a special report… but it’s only available for a limited time.

Click Here to Grab The Top 5 AI Stocks Report

SEC Filings (Institutional Ownership Changes) for Bone Biologics (NASDAQ:BBLG)

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Today's Range

Now: $0.71

$0.70

$0.73

50 Day Range

MA: N/A

52 Week Range

Now: $0.71

$0.57

$34.20

Volume

17,877 shs

Average Volume

65,355 shs

Market Capitalization

$2.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Who are the company insiders with the largest holdings of Bone Biologics?: Bone Biologics' top insider shareholders include:
Jeff Frelick (CEO)
Deina H Walsh (CFO)
Learn More about top insider investors at Bone Biologics.